Further reading

Endometriosis

The role of prostaglandin E2 in endometriosis
Sacco K, Portelli M, Pollacco J, Schembri-Wismayer P, Calleja-Agius J.
Gynecol Endocrinol. 2012 Feb;28(2):134-8. doi: 10.3109/09513590.2011.588753. Epub 2011 Oct 17. PMID: 22003899.

Endometriosis: recent advances that could accelerate diagnosis and improve care.
Griffiths MJ, Horne AW, Gibson DA, Roberts N, Saunders PTK
Trends Mol Med. 2024 Sep;30(9):875-889. doi: 10.1016/j.molmed.2024.06.008. Epub 2024 Jul 10. PMID: 38991858.

Pathophysiology, diagnosis, and management of endometriosis
Horne A, Missmer S
BMJ. 2022 Nov 14:379:e070750. doi: 10.1136/bmj-2022-070750. PMID: 36375827.

The inducible prostaglandin E synthase mPGES-1 regulates growth of endometrial tissues and angiogenesis in a mouse implantation model
Numao A, Hosono K, Suzuki T, Hayashi I, Uematsu S, Akira S, Ogino Y, Kawauchi H, Unno N, Majima M.
Biomed Pharmacother. 2011 Feb;65(1):77-84. doi: 10.1016/j.biopha.2010.12.008. Epub 2010 Dec 30. PMID: 21247731.

Identification of multiple and distinct defects in prostaglandin biosynthetic pathways in eutopic and ectopic endometrium of women with endometriosis
Rakhila H, Carli C, Daris M, Lemyre M, Leboeuf M, Akoum A.
Fertil Steril. 2013 Dec;100(6):1650-9.e1-2. doi: 10.1016/j.fertnstert.2013.08.016. Epub 2013 Sep 11. PMID: 24035605.

mPGES-1

Membrane prostaglandin E synthase-1: a novel therapeutic target
Samuelsson B, Morgenstern R, Jakobsson PJ.
Pharmacol Rev. 2007 Sep;59(3):207-24. doi: 10.1124/pr.59.3.1. PMID: 17878511.

A review on mPGES-1 inhibitors: From preclinical studies to clinical applications
Bergqvist F, Morgenstern R, Jakobsson PJ
Prostaglandins Other Lipid Mediat. 2020 Apr;147:106383. doi: 10.1016/j.prostaglandins.2019.106383. Epub 2019 Nov 4. PMID: 31698145.

Vipoglanstat (previously called GS-248, BI1029539)

Vipoglanstat, a non-hormonal treatment for endometriosis ready to start phase II (provided on request)
Edenius C, Ekström G, Stenberg P, Tornling G. EEC 2024

Vipoglanstat, a novel non-hormonal treatment in development for endometriosis targeting selective mPGES-1 inhibition (provided on request)
Ekström G, Edenius C, Stenberg P, Tornling G. SEUD 2024

First Time Disclosure of GS-248, an mPGES1 Inhibitor for the treatment of pain and inflammation. Pfau R. Poster, EFMC-ISMC 2022 (provided on request)

Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice
Gurusamy M, Nasseri S, Rampa DR, Feng H, Lee D, Pekcec A, Doods H, Wu D.
J Transl Med. 2021 Aug 9;19(1):340. doi: 10.1186/s12967-021-03016-9. PMID: 34372885; PMCID: PMC8351447

Inhibition of microsomal prostaglandin E synthase-1 (mPGES-1) by GS-248 reduces prostaglandin E2 biosynthesis while increasing prostacyclin in human subjects. (provided on request)
Edenius C, Ekström G, Kolmert J, Morgenstern R, Stenberg P, Jakobsson PJ, Tornling G. EULAR 2020

Inhibition of human microsomal PGE2 synthase-1 reduces seizure-induced increases of P glycoprotein expression and activity at the blood-brain barrier
Soldner E, Hartz A, Akanuma S-I, Pekcec A, Doods H, Kryscio R, Hosoya K-I, Bauer B
FASEB J. 2019 Dec;33(12):13966-13981. doi: 10.1096/fj.201901460RR. Epub 2019 Oct 22. PMID: 31638830; PMCID: PMC6894061.